TICKERNERD
Menu
JBIOJBIOHealthcare · Biotechnology

JBIO Stock Forecast: Jade Biosciences, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$14
−1.26% on the day

The 10 Wall Street analysts covering Jade Biosciences, Inc. hold a median 12-month price target of $47 — +234.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$894.2M
Ticker Nerd rank
26/ 100
Median analyst target
$47
Analysts covering
10
Revenue$0.0
Operating income−$58.9M
Net income−$55.8M
Free cash flow−$43.7M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.6%
1M
+0.1%
YTD
−8.9%
1Y
+42.7%
From 52W high
−47.6%
From 52W low
+57.1%
$9
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jade Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
26/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
57
Momentum
55
Value
50
Volatility
49
Size
45
Revisions
37
Growth
28
Issuance
27
Accruals
27

Quality (57): The business earns solid, repeatable profits on what it owns.

Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26JBIOHigh $77Median $47Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $40Median $47High $77

The green dot is the last close — the median target sits +234.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Oct 2026BTIGReiteratesBuy$77
1 Oct 2026HC Wainwright & Co.ReiteratesBuy$55
1 Oct 2026HC Wainwright & Co.ReiteratesBuy—
1 Oct 2026WedbushReiteratesOutperform—
1 Oct 2026WedbushReiteratesOutperform$47
11 Aug 2026WedbushMaintainsOutperform—
11 Aug 2026WedbushMaintainsOutperform$45 → $47
10 Aug 2026BTIGMaintainsBuy—
10 Aug 2026BTIGMaintainsBuy$74 → $77
15 June 2026UBSInitiatesBuy—
15 June 2026UBSInitiatesBuy$45
2 June 2026WedbushMaintainsOutperform—
1 June 2026BTIGMaintainsBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
27 May 2026BTIGReiteratesBuy—
11 May 2026GuggenheimMaintainsBuy—
11 May 2026WedbushMaintainsOutperform—
27 Apr 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

JBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

JBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Jade Biosciences, Inc. returned +42.7% against +12.4% for the S&P 500, dividends included.

JBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26JBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Jade Biosciences, Inc. (JBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.4×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.0×

Cheaper than 42% of US stocks

EV / EBITDA
−2.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−38.3%

Higher than 25% of US stocks

Return on assets
−36.4%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Jade Biosciences, Inc. (JBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jade Biosciences, Inc. has a market value of $894.2M and an enterprise value of $434.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$153.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$123.6M.

  • Shares outstanding: 63.6M.

  • Trailing P/E: −4.4×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Jade Biosciences, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

JBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JBIOJade Biosciences, Inc.$894.2M26
LTGOLatigo Biotherapeutics, Inc.$882.2M1
AKTSAktis Oncology, Inc.$880.5M2
GLUEMonte Rosa Therapeutics, Inc.$909.0M65
ANROAlto Neuroscience, Inc.$878.5M54
MGTXMeiraGTx Holdings Plc$878.4M79
KURAKura Oncology, Inc.$910.7M75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jade Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JBIO news & analysis

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

GlobeNewsWire · 21 Oct 2026positive

Jade Biosciences said three JADE101 posters will be presented at ASN Kidney Week 2026, covering its scientific rationale and clinical studies in IgA nephropathy. The company now expects to initiate the EVERGREEN Phase 3 trial in Q4 2026 and report interim JUNIPER Phase 2 data in Q2 2027.

Why it matters — The update gives JBIO watchers new timelines for JADE101’s Phase 3 initiation and Phase 2 interim data, alongside planned scientific presentations.

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

Seeking Alpha · 30 Sept 2026positive

Jade Biosciences (JBIO) discussed the JADE301 program profile and preclinical data in dermatomyositis, based on a Seeking Alpha transcript of the company's remarks. This follows the company's engagement on the drug candidate's development for the condition.

Why it matters — JBIO watchers would care because this provides insight into the JADE301 program's profile and the preclinical evidence supporting its potential in dermatomyositis, an area central to the company's development pipeline.

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

GlobeNewsWire · 30 Sept 2026positive

Jade Biosciences announced preclinical data for JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, presented at EADV 2026. The data showed high-affinity selective IFN-β binding, greater functional potency than a dazukibart comparator, approximately a 25-day half-life with predictable muscle distribution, and good tolerability in non-human primates. A Phase 1 healthy volunteer trial is expected to begin in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.

Why it matters — This preclinical characterization and the planned Phase 1 timelines give JBIO watchers an early read on the potential differentiation and advancement of a key pipeline candidate for dermatomyositis.

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Jade Biosciences, Inc. (JBIO) presented at Citigroup's Biopharma Back to School Summit 2026, with the event covered via a transcript published on Seeking Alpha. The presentation was part of the company's participation in an industry conference.

Why it matters — JBIO watchers would care because the conference presentation provides an opportunity to hear company representatives discuss their business in a formal investor setting.

Jade Biosciences to Participate in Upcoming Conferences

GlobeNewsWire · 1 Sept 2026neutral

Jade Biosciences, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its participation in upcoming conferences, including a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8 at 3:45 p.m. The announcement originated from San Francisco and Vancouver on September 1, 2026.

Why it matters — JBIO watchers would care because the company's scheduled conference participation offers opportunities for increased visibility and engagement with the investment community.

FAQ

Frequently asked questions about JBIO stock

What is the JBIO stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Jade Biosciences, Inc. have a median 12-month price target of $47, with estimates ranging from $40 to $77. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JBIO stock a buy right now?

Of the 10 analysts covering Jade Biosciences, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jade Biosciences, Inc. 26 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JBIO?

As at 31 Oct 2026, Jade Biosciences, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (57 of 100).

Will JBIO stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +234.3% from the last close, and Ticker Nerd's factor model ranks Jade Biosciences, Inc. 26 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JBIO stock forecast for 2030?

No analyst covering Jade Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $77 over the next 12 months.

How has JBIO stock performed over the past year?

Jade Biosciences, Inc. returned +42.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jade Biosciences, Inc. do?

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases.

What is the latest news on JBIO?

The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026". Jade Biosciences said three JADE101 posters will be presented at ASN Kidney Week 2026, covering its scientific rationale and clinical studies in IgA nephropathy. The company now expects to initiate the EVERGREEN Phase 3 trial in Q4 2026 and report interim JUNIPER Phase 2 data in Q2 2027.

Company

About Jade Biosciences, Inc.

Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders. The company’s lead candidate, JADE101, is being developed to inhibit APRIL, a protein linked to abnormal immune activity, while JADE201 and JADE301 are advancing through earlier-stage research for additional autoimmune indications. Jade Biosciences works as a development-focused biopharmaceutical company, relying on clinical research, preclinical testing, and collaboration agreements to advance its programs. Headquartered in Waltham, Massachusetts, the company serves the immunology and nephrology fields by pursuing targeted biologic therapies for patients with significant unmet medical needs.

CEO Mr. Tom Frohlich · 55 employees · United States · https://jadebiosciences.com